ClinicalTrials.gg
CompletedNCT02454556Updated Feb 24, 2017

A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART

A Phase 3 interventional study of FOLITIME® and Gonal-F® in Infertility, sponsored by Gema Biotech S.A.. Completed at 1 site in Argentina. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Gema Biotech S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Enrollment
21st of 30
106 · median 159
Started
2015
with 2 others
Phase 3
9 of 30
1 open now
Registered
20th of 30
by date
Lead sponsor
1 of 30
Gema Biotech S.A.

Among the 30 studies testing follitropin alfa in Infertility, this one is the 21st largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 20th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

This is an open-label, Phase 3, randomized, two arms, multicenter, prospective, experimental study of Folitime® (a new biosimilar formulation of r-hFSH, follitropin alfa) versus the original one (Gonal-f ®).

Read the detailed description

Follitropin alfa is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, nonidentical glycoproteins designated as the alfa- and beta-subunits. Similar to other glycoprotein hormones, FSH has a high degree of heterogeneity due to differences in the amount and/or composition of the carbohydrate residues, particularly sialic acid. FSH, the active component of r-hFSH is the most important hormone responsible for follicular recruitment and development. In order to obtain final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following the administration of r-hFSH when monitoring of the patient indicates that sufficient follicular development has occurred.

Secondary endpoints to be measured by the study are

Efficacy

  • Total dose of r-hFSH required,
  • Number of days of r-hFSH stimulation
  • Percentage of patients with need to increase or lower the dose of r-hFSH,
  • Number of treatment cycle cancellations and their reason
  • Fertilization rate
  • Number of fertilized oocytes
  • Number of good quality embryos
  • Number of embryos transferred
  • Implantation Rate
  • Biochemical pregnancy
  • Clinical pregnancy 10 weeks post embryo transfer
  • Pregnancy outcome

Safety

Incidence of

  • OHSS (and its severity)
  • Local reactions (pain, bruising, redness, itching, swelling)
  • Systemic drug adverse events

Tolerability

  • Frequency of patients who withdraw the study drug due to lack of tolerance
  • Frequency of patients who withdraw the study drug treatment due to any reason
  • Patient Reported Pain: measured by a Patients Visual Analog Scale (VAS)

Immunogenicity Measurement of possible antibodies against exogenous r-hFSH will be evaluated. Pharmacodynamics

  • Number and size distribution of follicles during treatment
  • Number and size distribution of follicles at the day of ovulation induction (uHCG)
  • Number of follicles >14 mm on the day of hCG injection.
  • Hormone parameters: serum levels of estradiol, luteinizing hormone and progesterone on the day of hCG injection
  • Metaphase II oocytes;
  • Number of good quality oocytes
03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Assisted reproduction technologies
  • Follicle stimulating hormone (FSH).
04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 38 years of age
  • Indication for controlled ovarian stimulation and IVF or intracytoplasmic sperm injection (ICSI)
  • Regular menstrual cycles (25-35 days)
  • History of a maximum of two fresh cycle treatments in the present series of assisted reproductive technologies (ART) at the day of first screening (thawed cycles are not subject to that criteria)
  • (BMI) ≥18 and ≤32 kg/m2
  • Basal FSH \<10 IU/L (cycle day 2-5)
  • Antral follicle count (AFC) ≥8 to ≤18 follicles with a diameter of \<10mm (sum of both ovaries) as measured on ultrasound (US) in the early follicular phase (day 1 of the stimulation cycle or of the last cycle previous to the treatment)
  • Documented history of infertility due to any of the following factors: tubal factor, male factor, unexplained infertility
  • Presence of both ovaries by ultrasonography and normal uterine cavity or abnormal uterine cavity without clinical significance according to the investigator's opinion (confirmed by hysterosalpingography, saline infusion sonography or hysteroscopy within 12 months before randomization) and normal uterine cavity by transvaginal ultrasound within 3 months of treatment
  • Male partner with semen analysis that is at least adequate for ICSI within 6 months prior to patient beginning down-regulation (invasive or surgical sperm retrieval, donor and/or cryopreserved sperm may be used)
  • Willingness to participate in the study and to comply with the study protocol
  • Signed prior to screening

Exclusion criteria

Exclusion Criteria:

  • Presence of pregnancy
  • History of or active polycystic ovary syndrome (PCOS)
  • AFC >18 follicles with a diameter of \<10 mm (both ovaries combined) as measured on US in the early follicular phase (menstrual cycle day 2-5) or during
  • History of >2 unsuccessful fresh ART retrieval cycles
  • History of poor response to gonadotropin treatment (defined as fewer than 5 oocytes retrieved in a previous attempt)
  • Any hormonal treatment within 1 month before the start of the FSH treatment, with the exception of levothyroxine)
  • Egg donor
  • Intrauterine leiomyomas ≥5 cm or otherwise pathology that could impair embryo implantation or pregnancy continuation
  • Previous history of OHSS
  • Ovarian cyst or enlargement of undetermined origin
  • History of recurrent spontaneous abortion (3 or more, even when unexplained)
  • Presence of endometriosis or hydrosalpinx
  • Neoplasia, including tumors of the hypothalamus and pituitary gland
  • Abnormal genital bleeding of undetermined origin
  • History of extrauterine pregnancy in the previous 3 months
  • Sex hormone dependent tumors of the reproductive tract and accessory organs.
  • Uncontrolled thyroid or adrenal dysfunction or presence of uncontrolled endocrine disorder
  • Known allergy or to FSH preparations or one of their or progesterone or to any of the excipients of the additional study medications
  • Clinically significant abnormal findings at Visit 1 that, in the opinion of the investigator, can affect trial resulkts or subject's safety
  • Administration of other products within the previous month or concomitant participation in another study protocol
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    FOLITIME®

    Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.

    Drug: FOLITIME®

  • Active comparator
    Gonal-F®

    Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.

    Drug: Gonal-F®

Interventions

  • Also known as: Follitropin alfa (r-hFSH)

  • Also known as: Follitropin alfa (r-hFSH)

06

What researchers measure

Primary outcomes

  1. Number of oocytes retrieved

    Time frame: 5 days

07

Study locations

1 site
  • Halitus Instituto Médico
    Buenos Aires, Caba C1122AAF, Argentina
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2015
First posted
May 27, 2015
Start
Apr 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02454556
Lead sponsor
Gema Biotech S.A.
Collaborators
QUID Quality in Drugs and Devices Latin American Consulting SRL
Responsible party
Sponsor
First posted
May 27, 2015
Start date
Apr 2015
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Feb 24, 2017

Study contacts

Sergio Pasqualini, MD
principal investigator · Halitus Instituto Medico

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion